Invivyd (IVVD) AI Stock Analysis

• Market Cap: $325.90M
• Dividend Yield: N/A
• Average Volume (3M): 5.69M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.88
• Revenue Growth: 332.71%
• EPS Growth: 75.73%
• Country: US
• Employees: 99
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 214,409,450
• 10 Day Avg. Volume: 4,028,033
• 30 Day Avg. Volume: 5,691,279
• PEG Ratio: 0.01
• Price to Book (P/B): 0.78
• Price to Sales (P/S): 2.07
• P/FCF Ratio: -0.31
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $10.00
• Price Target Upside: 532.91% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: ―

Invivyd's overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.

Positive Factors

Revenue Growth

The significant revenue growth marks a pivotal shift from no revenue in previous years, indicating successful product commercialization and market acceptance.

Regulatory Advances

Alignment with FDA for a rapid approval pathway enhances Invivyd's competitive position, potentially accelerating market entry and revenue generation for VYD2311.

Product Efficacy

PEMGARDA's efficacy against current variants supports its long-term viability in the COVID-19 treatment market, reinforcing Invivyd's product portfolio strength.

Negative Factors

Operational Losses

Ongoing operational losses and negative margins indicate inefficiencies that could hinder long-term profitability and require strategic cost management.

Cash Flow Challenges

Negative cash flow highlights liquidity challenges, potentially limiting Invivyd's ability to invest in growth and innovation without external financing.

Equity Decline

Declining equity levels pose a risk to financial stability, potentially affecting investor confidence and the company's ability to secure favorable financing terms.

Invivyd Business Overview & Revenue Model

Company Description

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

How the Company Makes Money

Invivyd generates revenue primarily through the development and commercialization of its therapeutic products. The company invests in research and development to create proprietary monoclonal antibodies that can be licensed or sold to healthcare providers, pharmaceutical companies, or directly to the market. Revenue streams may include product sales, licensing agreements, and potential partnerships or collaborations with other pharmaceutical companies. These partnerships can involve co-development or co-marketing arrangements, which can significantly contribute to the company's earnings by leveraging shared resources and expertise.

Invivyd Financial Statement Overview

Summary

Invivyd faces substantial financial challenges with significant losses and negative cash flows, despite recent revenue generation. While the balance sheet shows low leverage and strong cash reserves, consistent operational losses and cash flow inefficiencies pose considerable risks. Strategic improvements are critical for future stability.

Income Statement

Invivyd's financial performance shows a challenging trajectory. The company recorded its first revenue of $25.38 million in 2024 after having no revenue in previous years, indicating a significant growth. However, the company still faces substantial net losses, with a negative net profit margin due to high operational costs. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

Invivyd maintains a relatively strong equity position with a moderate debt load, as evidenced by a low debt-to-equity ratio. However, there has been a significant decrease in stockholders' equity over the years, and the equity ratio has declined, indicating potential risks if losses continue. The company's high cash reserves provide some financial stability.

Cash Flow

The company's cash flow situation is strained, with consistently negative free cash flow due to high operational cash outflows. The free cash flow to net income ratio remains unfavorable, indicating that the company is not generating cash from its operations. However, there is a positive trend in financing activities which have supported cash reserves.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	50.04M	25.38M	0.00	0.00	0.00	0.00
Gross Profit	46.71M	23.77M	-2.03M	-462.00K	-1.00K	0.00
EBITDA	-60.22M	-173.76M	-196.62M	-248.03M	-226.79M	-65.33M
Net Income	-59.86M	-169.93M	-198.64M	-234.60M	-234.29M	-65.32M
Balance Sheet
Total Assets	139.16M	129.51M	229.18M	383.17M	620.09M	117.38M
Cash, Cash Equivalents and Short-Term Investments	84.97M	69.35M	200.64M	371.99M	591.42M	114.99M
Total Debt	2.68M	1.30M	2.17M	3.72M	0.00	0.00
Total Liabilities	46.09M	61.98M	51.71M	27.20M	62.07M	182.63M
Stockholders Equity	93.07M	67.54M	177.47M	355.97M	558.02M	-65.25M
Cash Flow
Free Cash Flow	-80.44M	-170.63M	-173.78M	-221.69M	-184.82M	-14.57M
Operating Cash Flow	-80.29M	-170.49M	-173.16M	-219.99M	-184.74M	-14.57M
Investing Cash Flow	-150.00K	-140.00K	280.68M	-230.67M	-50.71M	0.00
Financing Cash Flow	58.53M	39.33M	1.04M	506.00K	662.68M	129.56M

Invivyd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.58
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVVD, the sentiment is Positive. The current price of 1.58 is below the 20-day moving average (MA) of 1.81, above the 50-day MA of 1.48, and above the 200-day MA of 0.98, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 47.19 is Neutral, neither overbought nor oversold. The STOCH value of 19.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IVVD.

Invivyd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FDMT	58 Neutral	$509.99M	―	-38.87%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LRMR	49 Neutral	$297.00M	―	-78.24%	―	―	-67.41%
DSGN	47 Neutral	$355.36M	-5.58	-29.83%	―	―	-40.26%
IMAB	45 Neutral	―	―	―	―	-100.00%	72.45%
IVVD	44 Neutral	$325.90M	―	-67.94%	―	332.71%	75.73%
RCKT	40 Underperform	$348.53M	-1.27	-69.65%	―	―	10.36%

Invivyd Corporate Events

Invivyd Secures $30 Million Loan from SVB

On April 18, 2025, Invivyd, Inc. entered into a $30 million loan agreement with Silicon Valley Bank, allowing for future capital drawdowns contingent on meeting specific conditions and milestones. This non-dilutive financing supports Invivyd’s strategic focus on enhancing per-share value and advancing its pipeline, including the monoclonal antibody candidate VYD2311, which is being developed for COVID-19 treatment and prevention.

Spark’s Take on IVVD Stock

According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.

Invivyd’s stock is under pressure due to significant financial difficulties, with ongoing losses and cash flow issues. The technical indicators suggest a bearish trend, and the valuation metrics highlight market concerns about future profitability. However, the appointment of Ajay Royan to the board is a positive corporate development that could improve strategic outcomes. Overall, the stock scores low due to financial and technical weaknesses, partially offset by potential strategic improvements.

To see Spark’s full report on IVVD stock, click here.

Invivyd Appoints Ajay Royan to Board of Directors

On March 22, 2025, Invivyd, Inc. appointed Ajay Royan, founder of Mithril Capital, to its Board of Directors, with his term expiring at the 2025 annual meeting of stockholders. Royan, a venture capitalist with a focus on healthcare, technology, and energy, will receive compensation consistent with other non-employee directors and was granted an option to acquire 100,000 shares of common stock. His appointment is expected to enhance Invivyd’s efforts to advance its monoclonal antibody technology platform, which aims to provide high-quality medicines for vulnerable populations affected by COVID-19 and other diseases.